Row 92278

Row ID: 92278 | Dataset Entry | Axioma AXP Content Repository

Content Data

This page contains data entry 92278 from the Axioma AXP content repository. The structured data below represents the complete record for this entry.

Idk. I'm quite skeptical. The most concerning thing in DD is that we are just referring to this as "lung cancer" like we treat them all the same. So much more nuance to this and where the therapy ultimately lands in the NCCN and other national guidelines is going to dictate uptick.

These aren't disease states that that I'm super knowledgeable about but I also see that anktiva is competing against Nadofaragene firadenovec for BCG resistant bladder cancer. More established therapy.

Again, I don't know OPs background but there's so much nuance and moving parts in pharma investment. The DD doesn't do an overall good job because it's not giving background on relevant therapies in this space.

FieldValue
text Idk. I'm quite skeptical. The most concerning thing in DD is that we are just referring to this as "lung cancer" like we treat them all the same. So much more nuance to this and where the therapy ultimately lands in the NCCN and other national guidelines is going to dictate uptick. These aren't disease states that that I'm super knowledgeable about but I also see that anktiva is competing against Nadofaragene firadenovec for BCG resistant bladder cancer. More established therapy. Again, I d…
label r/wallstreetbets
dataType comment
communityName r/wallstreetbets
datetime 2024-05-25
username_encoded Z0FBQUFBQm5Lak1zRHhXQm9obkg0WXh1NEx1YWkzeGdhT19GVFU3UThJQ0ZUbnFDWW83LUh3SzFxYTRoWUh0aTUyR25FMGtiRWpWY0U3alk3Y24yWjl4eG9aR0RrYlZyN3c9PQ==
url_encoded Z0FBQUFBQm5Lak8talRBNkIyaENYOFh2MGI3LWZxZjBuZ0lJWGM5TFlzQzVVd21WSU93WWN3T08wQk9QVVNNUU5nUXk3eG16RzQ5a09FQzdwU2hNaDB3UkZzTC1hRzYtUzJnZHZPQUNjWWk3RVA1V1c3LTlmdUFQNnh6SmVSRzZodVN4OWN6azc5Wk9FZER1V2tYUksxZURWNXAxeWlWZUVEVWtQSlRSS0QyWjFuakdsTWY5TV9fT3dqdnRXRHgzMDBmZTU1YUZxdWp0S0dOdWozZzNNbVoxWi1zUnV0UUdUZz09

Raw Record

{
  "text": "Idk. I'm quite skeptical. The most concerning thing in DD is that we are just referring to this as \"lung cancer\" like we treat them all the same. So much more nuance to this and where the therapy ultimately lands in the NCCN and other national guidelines is going to dictate uptick. \n\nThese aren't disease states that that I'm super knowledgeable about but I also see that anktiva is competing against Nadofaragene firadenovec for BCG resistant bladder cancer.  More established therapy. \n\nAgain, I don't know OPs background but there's so much nuance and moving parts in pharma investment. The DD doesn't do an overall good job because it's not giving background on relevant therapies in this space.",
  "label": "r/wallstreetbets",
  "dataType": "comment",
  "communityName": "r/wallstreetbets",
  "datetime": "2024-05-25",
  "username_encoded": "Z0FBQUFBQm5Lak1zRHhXQm9obkg0WXh1NEx1YWkzeGdhT19GVFU3UThJQ0ZUbnFDWW83LUh3SzFxYTRoWUh0aTUyR25FMGtiRWpWY0U3alk3Y24yWjl4eG9aR0RrYlZyN3c9PQ==",
  "url_encoded": "Z0FBQUFBQm5Lak8talRBNkIyaENYOFh2MGI3LWZxZjBuZ0lJWGM5TFlzQzVVd21WSU93WWN3T08wQk9QVVNNUU5nUXk3eG16RzQ5a09FQzdwU2hNaDB3UkZzTC1hRzYtUzJnZHZPQUNjWWk3RVA1V1c3LTlmdUFQNnh6SmVSRzZodVN4OWN6azc5Wk9FZER1V2tYUksxZURWNXAxeWlWZUVEVWtQSlRSS0QyWjFuakdsTWY5TV9fT3dqdnRXRHgzMDBmZTU1YUZxdWp0S0dOdWozZzNNbVoxWi1zUnV0UUdUZz09"
}
Explore Dataset Explore Row

Entry Information